Vaccinex, Inc. (VCNX)
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
$9.76M
Dr. Maurice Zauderer Ph.D.
39.00
Rochester, NY
Aug 09, 2018
-1.43
$-3.96
0.56
0.79
-3,345.08%
-2.45
0.02
-125.70
16.92
0.57
-704.80%
-644.81%
Similar stocks (12)
Erasca, Inc.
ERAS
Eledon Pharmaceuticals, Inc.
ELDN
Anebulo Pharmaceuticals, Inc.
ANEB
ZIVO Bioscience, Inc.
ZIVO
Protara Therapeutics, Inc.
TARA
Surrozen, Inc.
SRZN
RenovoRx, Inc.
RNXT
SAB Biotherapeutics, Inc.
SABS
GeoVax Labs, Inc.
GOVX
Monopar Therapeutics Inc.
MNPR
Forte Biosciences, Inc.
FBRX
Salarius Pharmaceuticals, Inc.
SLRX
ETF Exposure (2)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (12)
Erasca, Inc.
ERAS
Eledon Pharmaceuticals, Inc.
ELDN
Anebulo Pharmaceuticals, Inc.
ANEB
ZIVO Bioscience, Inc.
ZIVO
Protara Therapeutics, Inc.
TARA
Surrozen, Inc.
SRZN
RenovoRx, Inc.
RNXT
SAB Biotherapeutics, Inc.
SABS
GeoVax Labs, Inc.
GOVX
Monopar Therapeutics Inc.
MNPR
Forte Biosciences, Inc.
FBRX
Salarius Pharmaceuticals, Inc.
SLRX
ETF Exposure (2)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%